Literature DB >> 9679557

Glutathione based approaches to improving cancer treatment.

L M Kauvar1, A S Morgan, P E Sanderson, W D Henner.   

Abstract

The use of cytotoxic chemotherapy for cancer therapy has been very successful in the treatment and often cure of patients with particular neoplasms, such as testicular carcinomas and some lymphomas. In addition, the use of adjuvant chemotherapy in patients whose primary tumor has been surgically removed contributes significantly to cure rates in some of the more common malignancies such as breast carcinoma and colon cancer. Nonetheless, for most patients with metastatic malignancies, current antineoplastic drugs provide only brief remissions with few or no long term cures. In addition, the side effects of therapy lead to substantial morbidity in nearly all patients. Insights derived from model system studies on two glutathione based lead compounds, TER286 and TER199, suggest new clinical strategies and raise interesting basic research questions regarding the cell biology foundations of cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9679557     DOI: 10.1016/s0009-2797(97)00163-4

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  7 in total

Review 1.  New agents in myelodysplastic syndromes.

Authors:  Elias Jabbour; Francis J Giles
Journal:  Curr Hematol Malig Rep       Date:  2006-03       Impact factor: 3.952

Review 2.  The role of glutathione-S-transferase in anti-cancer drug resistance.

Authors:  Danyelle M Townsend; Kenneth D Tew
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

3.  Glutathione S-transferase P1-1 expression modulates sensitivity of human kidney 293 cells to photodynamic therapy with hypericin.

Authors:  Michael J Dabrowski; Dean Maeda; John Zebala; Weiya Doug Lu; Sumit Mahajan; Terrance J Kavanagh; William M Atkins
Journal:  Arch Biochem Biophys       Date:  2006-03-03       Impact factor: 4.013

Review 4.  Glutathione analogues in cancer treatment.

Authors:  David Hamilton; Gerald Batist
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

5.  Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp.

Authors:  Khalid O Alfarouk; Christian-Martin Stock; Sophie Taylor; Megan Walsh; Abdel Khalig Muddathir; Daniel Verduzco; Adil H H Bashir; Osama Y Mohammed; Gamal O Elhassan; Salvador Harguindey; Stephan J Reshkin; Muntaser E Ibrahim; Cyril Rauch
Journal:  Cancer Cell Int       Date:  2015-07-15       Impact factor: 5.722

6.  GSTT1 null and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients.

Authors:  Shahid M Baba; Arshad A Pandith; Zafar A Shah; Sajad A Geelani; Javid R Bhat; Ayaz Gul; Sameer A Guru; Hamed A El-Serehy; Abid M Koul; Sheikh Mansoor
Journal:  Front Oncol       Date:  2021-10-14       Impact factor: 6.244

7.  Development of Telintra as an Inhibitor of Glutathione S-Transferase P.

Authors:  Jie Zhang; Zhi-Wei Ye; Yvonne Janssen-Heininger; Danyelle M Townsend; Kenneth D Tew
Journal:  Handb Exp Pharmacol       Date:  2021
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.